OakChart

Tyra Biosciences Inc

TYRAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 2:50 PM ET

21.10+0.10 (0.46%)
2026-11-11 20:50 CET
Market cap
1,253.21 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-169.82 USD m
Free cash flow, TTM
-119.78 USD m
EPS diluted, TTM
-2.63
P/E
-
Compare

Price

TYRA against its 20, 50 and 200-day averages
2050200miss
20.0025.0030.0035.003.0M6.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TYRAclose 21.1020-day 20.8150-day 21.96200-day 29.5321.10

48.1% under the 52-week high of 40.65 on 1 Apr 2026. 52-week low 13.83 on 11 Nov 2025. Last 15 sessions, 14.7% high to low

Profile

TYRA
52-week range, 27% of the way up
13.8340.65

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNAP, enables the rapid and precise refinement of structural design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

IndexRUT
Employees87
IPOSep 15, 2021
Beta0.67
ATR, 14d1.14
Rel volume0.39
Short float21.63%
Insider own23.30%
Inst own96.62%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.45B
Enterprise Value755.31M
Income-169.82M
Sales0.00M
Book/sh10.04
Cash/sh10.19
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees87
IPOSep 15, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.10
P/C2.07
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio23.93
Current Ratio23.93
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.63
EPS next Y-2.98
EPS next Q-0.72
EPS this Y-35.53%
EPS next Y-9.54%
EPS next 5Y-18.15%
EPS past 3/5Y-15.07% -55.76%
Sales past 3/5Y- -
EPS Y/Y TTM-40.04%
Sales Y/Y TTM-
EPS Q/Q-47.82%
Sales Q/Q-
EarningsNov 10 BMO
EPS/Sales Surpr.-10.66% -

Ownership

Insider Own23.30%
Insider Trans0.01%
Inst Own96.62%
Inst Trans6.84%
ROA-32.99%
ROE-34.89%
ROIC-24.34%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA201.38%
SMA50-3.92%
SMA200-28.56%
Trades-

Technical

Shs Outstand68.98M
Shs Float45.77M
Short Float21.63%
Short Ratio11.87
Short Interest9.90M
52W High40.65 -48.10%
52W Low13.83 52.54%
Volatility6.46% 5.11%
ATR (14)1.14
RSI (14)48.78
Beta0.67
Rel Volume0.39
Avg Volume834.17K
Volume268,359

Performance

Perf Week-1.99%
Perf Month13.67%
Perf Quarter-15.68%
Perf Half Y-41.71%
Perf YTD-19.75%
Perf Year39.44%
Perf 3Y79.39%
Perf 5Y-25.24%
Perf 10Y-
Recom1.20
Target Price47.45
Prev Close21.00
Price21.10
Change %0.46%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
May 19, 2026InitiatedWWolfe ResearchPeer Perform
Apr 15, 2026InitiatedGGuggenheimBuy$54+156.0%
Apr 06, 2026InitiatedCCanaccord GenuityBuy$50+137.0%
Feb 24, 2026InitiatedCCantor FitzgeraldOverweight
Feb 10, 2026InitiatedWWilliam BlairOutperform
Jan 28, 2026InitiatedBBarclaysOverweight$59+179.7%
Sep 03, 2025InitiatedRRaymond JamesStrong Buy$35+65.9%
May 21, 2025ResumedPPiper SandlerOverweight$33+56.4%
Jan 07, 2025InitiatedUUBSBuy$28+32.7%
Oct 18, 2024UpgradeBBofA SecuritiesNeutral → Buy$22 → $31+46.9%

Peers

Mkt cap
TickerCompanyMkt cap
BBIOBridgeBio Pharma Inc15.45B
BMRNBiomarin Pharmaceutical Inc11.26B
ASNDAscendis Pharma A/S16.91B
RLAYRelay Therapeutics Inc4.40B
URGNUroGen Pharma Ltd1.27B
CGONCg Oncology Inc6.56B
INCYIncyte Corp24.92B
ELVNEnliven Therapeutics Inc3.80B
TNGXTango Therapeutics Inc4.43B
JNJJohnson & Johnson673.97B

Insider trading

latest 14 of 28
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Verjee RehanDirectorSep 09 '26Buy20.5897220,000972Sep 11 04:30 PM
NEXTECH VI ONCOLOGY SCSPShareholderJun 26 '26Proposed Sale30.94308,3799,541,246Jun 26 04:59 PM
NEXTECH VI ONCOLOGY SCSPShareholderJun 01 '26Proposed Sale33.41300,00010,023,000Jun 01 04:16 PM
Daniel BensenOfficerMay 12 '26Proposed Sale34.258,000274,000May 12 05:33 PM
Daniel BensenOfficerApr 13 '26Proposed Sale35.628,000285,000Apr 13 04:44 PM
KAPLAN GILLADirectorMar 25 '26Option Exercise2.2514,29532,16442,526Mar 27 04:44 PM
KAPLAN GILLADirectorMar 25 '26Sale36.9714,295528,50628,231Mar 27 04:44 PM
GILLA KAPLANDirectorMar 26 '26Proposed Sale37.7553,1722,007,153Mar 26 04:04 PM
GILLA KAPLANDirectorMar 25 '26Proposed Sale36.9714,295528,506Mar 25 05:36 PM
Daniel BensenOfficerMar 12 '26Proposed Sale35.388,000283,000Mar 12 05:42 PM
Bensen DanielChief Discovery OfficerFeb 12 '26Sale32.878,000262,965146,981Feb 13 04:30 PM
Daniel BensenOfficerFeb 12 '26Proposed Sale32.758,000262,000Feb 12 04:52 PM
Bensen DanielChief Discovery OfficerJan 12 '26Sale28.528,000228,186154,981Jan 20 04:30 PM
Daniel BensenOfficerJan 12 '26Proposed Sale29.008,000232,000Jan 12 05:38 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.740-0.669-0.7400.000.0015
2026Q22026-08-04-0.690-0.650-0.6900.000.0015
2026Q12026-05-13-0.640-0.588-0.6370.000.0014
2025Q42026-03-02-0.570-0.532-0.5660.000.0011
2025Q32025-11-05-0.500-0.498-0.5010.000.008
2025Q22025-08-14-0.470-0.529-0.4720.000.008
2025Q12025-05-08-0.470-0.486-0.4740.000.006
2024Q42025-03-27-0.430-0.474-0.4330.000.007
2024Q32024-11-07-0.410-0.399-0.4080.000.007
2024Q22024-08-07-0.320-0.408-0.3190.000.006
2024Q12024-05-09-0.350-0.455-0.3480.000.006
2023Q42024-03-19-0.530-0.480-0.5310.000.006
2023Q32023-11-07-0.490-0.353-0.4930.000.006
2023Q22023-08-10-0.310-0.338-0.3120.000.006
2023Q12023-05-04-0.280-0.366-0.2800.000.005
2022Q42023-03-22-0.310-0.360-0.3060.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-1.910-0.383-0.6350.000.00
2022FY-1.320-1.370-1.3210.000.00
2023FY-1.620-1.577-1.6190.000.00
2024FY-1.510-1.554-1.5110.000.00
2025FY-2.010-1.979-2.0120.000.00
2026FY--2.724--0.00
2027FY--2.984--0.00
2028FY--3.315--2.19
2029FY--3.109--37.63
2030FY--1.418--231.23

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-109000.000.000.00
2026Q4S2026-08-059000.000.000.00
2026Q4S2026-07-219000.000.000.00
2026Q4S2026-06-1610000.000.000.00
2026Q4S2026-06-119000.000.000.00
2026Q4S2026-06-1010000.000.000.00
2026Q4S2026-05-139000.000.000.00
2026Q4S2026-04-139000.000.000.00
2026Q4S2026-03-058000.000.000.00
2026Q4S2026-03-037000.000.000.00
2026Q4S2026-02-236000.000.000.00
2026Q4S2026-02-065000.000.000.00
2026Q4S2025-11-204000.000.000.00
2026Q4S2025-11-113000.000.000.00

Estimate history

EPS, annual-0.096-0.22-0.635-1.321-1.619-1.511-2.012-2.6324
Period2019202020212022202320242025TTM
EPS, quarterly-0.408-0.433-0.474-0.472-0.501-0.566-0.637-0.69-0.74
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual42.53542.53541.44142.35443.02550.7553.70668.982
Period2019202020212022202320242025MRQ
Shares, quarterly52.87250.7553.0953.23353.31853.70659.4759.66368.982
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.540.550.520.350.300.140.050.01
Gross Profit-0.54-0.55-0.52-0.35-0.30-0.14-0.05-0.01
Selling, General and Administrative Excl. Other181.86132.22103.6679.5958.6326.159.253.11
Research and Development143.46102.3879.5662.1642.7120.507.161.78
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-182.40-132.76-104.18-79.94-58.93-26.29-9.30-3.12
Interest Expense0.000.000.000.000.00-0.000.00
Unusual Expense0.000.000.000.000.000.000.010.93
Net Income Before Taxes-169.82-119.95-86.48-69.13-55.33-26.29-9.34-4.07
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-169.82-119.95-86.48-69.13-55.33-26.29-9.34-4.07
Net Income From Continuing Operations-169.82-119.95-86.48-69.13-55.33-26.29-9.34-4.07
Net Income-169.82-119.95-86.48-69.13-55.33-26.29-9.34-4.07
EPS (Recurring)-2.46-2.01-1.51-1.62-1.32-0.63-0.22-0.08
EPS (Basic, Before Extraordinaries)-2.63-2.01-1.51-1.62-1.32-0.63-0.22-0.10
EPS (Diluted)-2.63-2.01-1.51-1.62-1.32-0.63-0.22-0.10
EBITDA-181.86-132.22-103.66-79.59-58.63-26.15-9.25-3.11
Non-Operating Income (Expense)12.5812.8117.7010.813.60-0.01-0.02-0.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense37.8628.0122.8013.5310.592.890.44-
Shares Outstanding68.9853.7150.7543.0242.3541.4442.5442.54
Market Capitalization1,253.211,253.21734.92594.57320.24579.79574.02-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.130.140.140.130.130.140.140.14
Gross Profit-0.13-0.14-0.14-0.13-0.13-0.14-0.14-0.14
Selling, General and Administrative Excl. Other54.7648.8741.8636.3832.8131.3131.7129.60
Research and Development43.0139.0633.3328.0525.3424.1724.8222.04
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-54.88-49.00-42.00-36.52-32.94-31.45-31.85-29.74
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-51.12-45.56-39.30-33.83-29.87-28.10-28.15-25.57
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-51.12-45.56-39.30-33.83-29.87-28.10-28.15-25.57
Net Income From Continuing Operations-51.12-45.56-39.30-33.83-29.87-28.10-28.15-25.57
Net Income-51.12-45.56-39.30-33.83-29.87-28.10-28.15-25.57
EPS (Recurring)-0.74-0.69-0.64-0.57-0.50-0.47-0.47-0.43
EPS (Basic, Before Extraordinaries)-0.74-0.69-0.64-0.57-0.50-0.47-0.47-0.43
EPS (Diluted)-0.74-0.69-0.64-0.57-0.50-0.47-0.47-0.43
EBITDA-54.76-48.87-41.86-36.38-32.81-31.31-31.71-29.60
Non-Operating Income (Expense)3.763.442.692.683.083.353.704.17
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense12.1610.237.857.637.586.386.426.70
Shares Outstanding68.9859.6659.4753.7153.3253.2353.0950.75
Market Capitalization1,253.211,899.462,056.961,401.74744.74508.91471.97734.92

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments256.00341.44203.47251.21302.1815.220.11
Short Term Receivables1.902.000.700.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets7.554.027.506.081.880.060.02
Total Current Assets265.45347.46211.67257.29304.0615.280.13
Net Property, Plant & Equipment6.897.728.153.542.090.470.28
Total Investments and Advances1.001.001.001.000.240.240.00
Intangible Assets-----0.00-
Deferred Tax Assets1.441.54--0.26--
Other Assets9.277.385.034.350.310.020.12
Total Assets284.05365.10225.86266.18306.9616.010.53
Short Term Debt Incl. Current Port. of LT Debt0.470.410.280.140.200.140.14
Accounts Payable1.180.594.661.150.600.660.33
Other Current Liabilities16.4413.5910.394.422.811.054.69
Total Current Liabilities18.0914.5915.335.703.621.865.16
Long Term Debt5.345.816.222.480.9827.650.11
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities1.441.54--0.26--
Other Liabilities0.000.000.050.170.370.140.00
Total Liabilities24.8721.9521.598.355.2329.655.27
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity259.18343.15204.26257.83301.74-13.64-4.74
Total Shareholders Equity259.18343.15204.26257.83301.74-13.64-4.74
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity259.18343.15204.26257.83301.74-13.64-4.74
Total Liabilities & Stockholders Equity284.05365.10225.86266.18306.9616.010.53
Book Value Per Share4.836.764.756.097.28-0.32-0.11
Tangible Book Value Per Share4.836.764.756.097.28-0.32-0.11
Full-Time Employees8760493825--
Price to Book Ratio2.092.032.681.201.931.85-
Return on Assets-36.96-29.27-28.10-19.31-16.28-112.90-
Return on Equity-39.83-31.60-29.92-19.77-18.25--
Return on Invested Capital-45.35-24.78-32.85-21.25-8.69-66.62-
Quick Ratio14.6723.8113.8045.1384.098.220.02
Current Ratio14.6723.8113.8045.1384.098.220.02

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-169.82-119.95-86.48-69.13-55.33-26.29-9.34-4.07
Depreciation0.540.550.520.350.300.140.050.01
Other Funds (Non Cash)37.3725.8916.9212.2810.592.890.460.93
Funds from Operations-131.91-93.51-69.05-56.50-44.44-23.26-8.83-3.12
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital12.43-1.63-0.736.36-5.85-0.481.070.51
Cash from Operating Activities-119.48-95.14-69.77-50.14-50.28-23.75-7.76-2.62
Capital Expenditures-0.30-0.14-0.66-0.77-0.56-0.66-0.31-0.02
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.020.000.00
Purchase or Sale of Investments-32.7972.60-97.74-143.840.000.000.000.00
Purchase of Investments-212.38-101.25-263.62-143.840.000.000.000.00
Sale Or Maturity of Investments179.59173.86165.880.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-33.0972.46-98.40-144.60-0.56-0.65-0.31-0.02
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock546.648.10202.141.540.63311.3823.450.17
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock546.648.10202.141.540.63311.3823.450.17
Proceedsfrom Stock Options165.160.00199.580.000.00310.8423.310.17
Issuance or Reduction of Debt, Net0.000.000.000.000.00-0.01-0.02-0.01
Change in Long Term Debt0.000.000.000.000.00-0.010.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00-0.010.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.030.000.00
Other Financing Activities Uses0.000.000.000.000.00-0.030.000.00
Cash from Financing Activities546.648.10202.141.540.63311.3523.430.16
Net Change in Cash394.06-14.5833.96-193.21-50.21286.9615.36-2.48
Free Cash Flow-119.78-95.28-70.44-50.91-50.84-24.41-8.07-2.64
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments700.66354.06383.47256.00274.92296.27
Short Term Receivables2.202.502.701.902.201.70
Inventories0.000.000.000.000.000.00
Other Current Assets8.7510.418.457.554.094.18
Total Current Assets711.62366.97394.61265.45281.22302.15
Net Property, Plant & Equipment6.266.486.666.897.047.24
Total Investments and Advances0.880.880.881.001.001.00
Deferred Tax Assets---1.44--
Other Assets8.769.039.889.2712.5911.11
Total Assets727.53383.36412.04284.05301.85321.50
Short Term Debt Incl. Current Port. of LT Debt0.520.500.490.470.460.44
Accounts Payable3.302.333.641.181.992.25
Other Current Liabilities25.9221.7815.1316.4413.4311.08
Total Current Liabilities29.7424.6219.2618.0915.8813.77
Long Term Debt4.945.085.215.345.465.58
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---1.44--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities34.6829.7024.4624.8721.3419.35
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity692.84353.66387.57259.18280.51302.15
Total Shareholders Equity692.84353.66387.57259.18280.51302.15
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity692.84353.66387.57259.18280.51302.15
Total Liabilities & Stockholders Equity727.53383.36412.04284.05301.85321.50
Book Value Per Share10.045.936.524.835.265.68
Tangible Book Value Per Share10.045.936.524.835.265.68
Full-Time Employees---87--
Price to Book Ratio2.094.907.945.002.461.57
Return on Assets-32.99-42.15-34.71-36.96-32.73-29.65
Return on Equity-34.89-45.31-36.87-39.83-34.75-31.21
Return on Invested Capital-7.33-12.70-10.01-12.79-10.44-9.13
Quick Ratio23.9314.9120.4914.6717.7121.94
Current Ratio23.9314.9120.4914.6717.7121.94

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-51.12-45.56-39.30-33.83-29.87-28.10
Depreciation0.130.140.140.130.130.14
Other Funds (Non Cash)12.0210.037.827.507.165.67
Funds from Operations-38.97-35.39-31.34-26.20-22.58-22.29
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital6.764.32-1.232.580.20-1.39
Cash from Operating Activities-32.21-31.08-32.57-23.62-22.38-23.68
Capital Expenditures-0.09-0.07-0.09-0.06-0.04-0.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments35.0117.92-120.1634.43-14.7720.90
Purchase of Investments-18.99-22.08-162.21-9.11-65.17-20.11
Sale Or Maturity of Investments54.0040.0042.0543.5450.4141.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities34.9217.85-120.2434.38-14.8120.87
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock379.472.10160.384.680.650.58
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock379.472.10160.384.680.650.58
Proceedsfrom Stock Options17.310.00147.850.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities379.472.10160.384.680.650.58
Net Change in Cash382.18-11.127.5715.44-36.54-2.23
Free Cash Flow-32.30-31.14-32.66-23.68-22.42-23.71

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3021.63%9.9M45.8M867.79K
2026-10-1520.75%9.5M45.8M842.49K
2026-09-3020.57%9.4M45.8M848.87K
2026-09-1521.58%9.9M45.8M877.12K
2026-08-3121.59%9.4M43.7M770.00K
2026-08-1422.16%9.7M43.7M839.20K
2026-07-3120.86%9.2M44.3M811.40K
2026-07-1522.48%9.9M44.2M930.31K
2026-06-3026.99%11.9M44.2M997.73K
2026-06-1522.33%9.9M44.2M959.35K
2026-05-2921.01%9.3M44.2M1.05M
2026-05-1518.26%8.1M44.2M1.07M
2026-04-3019.49%7.7M39.6M1.09M
2026-04-1520.86%7.7M37.0M1.03M
2026-03-3122.47%8.3M36.8M961.00K
2026-03-1318.63%6.9M36.8M857.61K
2026-02-2715.41%5.7M36.8M657.34K
2026-02-1314.09%5.1M36.5M642.24K
2026-01-3013.75%5.0M36.5M554.78K
2026-01-1513.92%5.1M36.5M475.39K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call7.5011.1016.000.009.9800.000.000.926-0.2050.005
call10.008.5013.400.007.4090.000.000.888-0.2830.006
call12.506.0010.800.005.4370.000.000.846-0.2760.008
call15.003.508.309.314.2763.000.000.795-0.2580.009
call17.501.156.003.503.3538.000.000.729-0.2320.011
call20.000.004.901.803.30622.000.000.668-0.2830.012
call22.500.004.901.004.0701130.000.588-0.2790.013
call25.000.004.900.104.65818.000.000.562-0.3410.013
call27.500.004.900.455.2252.000.000.539-0.3820.013
call30.000.003.500.204.40142.000.000.447-0.3060.014
call32.500.004.900.354.7901.000.000.431-0.3500.013
call35.000.000.500.155.03624.000.000.419-0.3460.013
call37.500.004.900.002.7050.000.000.131-0.1060.007
call40.000.004.900.502.92123.000.000.124-0.1100.007
call42.500.004.900.453.0571.000.000.119-0.1130.007
call45.000.004.900.403.2796.000.000.115-0.1170.006
call50.000.004.900.403.5756.000.000.108-0.1220.006
call55.000.004.900.403.8461.000.000.103-0.1270.006
put7.500.004.900.0010.8100.000.00-0.072-0.2750.005
put10.000.004.800.107.8141.000.00-0.111-0.2590.007
put12.500.004.900.156.3511.000.00-0.152-0.2740.008
put15.000.004.900.454.95214.000.00-0.202-0.2560.009
put17.500.102.900.253.7863.000.00-0.270-0.2310.011
put20.000.004.901.204.3911980.00-0.338-0.2790.012
put22.500.004.902.003.0444.000.00-0.417-0.2860.013
put25.001.656.504.003.1065.000.00-0.438-0.3390.013
put27.504.008.505.853.0491.000.00-0.465-0.3800.013
put30.006.6011.508.083.8140.000.00-0.553-0.3300.013
put32.509.1014.000.004.1850.000.00-0.569-0.3570.013
put35.0011.5016.5013.004.5110.000.00-0.861-0.0990.007
put37.5014.0018.900.004.7590.000.00-0.869-0.1040.007
put40.0016.5021.4011.805.0090.000.00-0.876-0.1080.007
put42.5019.0023.900.005.2380.000.00-0.881-0.1120.007
put45.0021.5026.200.005.0120.000.00-0.885-0.1140.006
put50.0026.5031.4019.765.8220.000.00-0.892-0.1190.006
put55.0031.5036.200.005.8830.000.00-0.897-0.1230.006

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-27SCHEDULE 13G/ASEC
2026-09-21SCHEDULE 13GSEC
2026-09-17SCHEDULE 13D/ASEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-17SCHEDULE 13GSEC
2026-09-158-KCurrent report2026-09-14SEC
2026-09-15424B5SEC
2026-09-14FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-09-14S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-04424B5SEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-30SCHEDULE 13GSEC
2026-06-26144Filing for proposed sale of securities under Rule 144.SEC
2026-06-028-KCurrent report2026-05-28SEC
2026-06-01144Filing for proposed sale of securities under Rule 144.SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-28SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0920.00K100
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-0300528.51K1
2026-0200262.96K1
2026-0100228.19K1
2025-1200431.16K2
2025-11009.14M6

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.20.51%
FMR LLC17.66%
Jupiter Topco LLC7.32%
Alta Partners Management Company, L.P.6.43%
Nextech Invest Ltd.5.98%
TCG Crossover Management, LLC5.46%
BlackRock, Inc.5.10%
PRICE T ROWE ASSOCIATES INC /MD/4.68%
STATE STREET CORP3.60%
Commodore Capital LP3.15%

Funds

Fund% owned
Fidelity OTC Portfolio5.54%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.34%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.91%
iShares Russell 2000 ETF1.59%
T. Rowe Price New Horizons Fund, Inc.1.33%
Fidelity Advisor Equity Growth Fund1.14%
VIP Growth Portfolio1.06%
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund0.94%
Hood River Small-Cap Growth Fund0.83%
Fidelity Small Cap Index Fund0.68%

OakChart. TYRA. Cached 15 minutes.